CClinicalTrials.gg
Sign In
Status unknownNCT03769987REASUpdated Dec 10, 2018

Registry for Advanced Sarcodiosis

An observational study in Sarcoidosis, sponsored by University of Cincinnati. Status unknown at 1 site in United States. Open to participants aged 15 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-12-10.

Sponsored by University of Cincinnati · Observational

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
800
Ages
15 Years to 100 Years
Sex
All
01

Study summary

Registry with evaluation and genetic information of patients with advanced sarcoidosis and matched sarcoidosis

02

Conditions studied

  • Sarcoidosis

Browse trials for

Keywords

  • neurosarcoidosis, pulmonary hyeprtension, infliximab, repository corticotropin
03

In context

Sarcoidosis

278 studies on the registry are indexed under Sarcoidosis; 57 are open to participants now.

This study's planned enrollment of 800 is above the median of 125 across 106 observational studies indexed under Sarcoidosis.

Browse Sarcoidosis studies →

Lead sponsor

University of Cincinnati is the lead sponsor of 314 studies on the registry; 43 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Advanced sarcoidosis is defined by the presence of one or more of the following features:

  1. Advanced pulmonary disease as defined by one or more of the following
  2. Symptomatic cardiac disease due to sarcoidosis by either MRI or PET scanning and
  3. Symptomatic neurologic disease
  4. Patients who have received third line therapy (anti-TNF antibodies, rituximab, or RCI)

Inclusion criteria

  • Patients with diagnosis of sarcoidosis based on ATS/WASOG criteria 22
  • Age ≥ 18 years.
  • Life expectancy of at least 2 years.
  • Pulmonary function tests (spirometry) within one month of entry or willing to under pulmonary function testing on the day of study enrollment
  • Sarcoidosis as characterized as either advanced or non-advanced (see protocol for definition of advanced disease)
  • Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion criteria

Exclusion criteria

  • Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator
  • Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
  • Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
800 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • Otherobservation

    observe patients every 6 months

06

What researchers measure

Primary outcomes

  1. Death

    Determine how many people die during follow up

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03769987
Lead sponsor
University of Cincinnati
Responsible party
Robert P Baughman (Professor, University of Cincinnati) — Principal investigator
First posted
Dec 10, 2018
Start date
Jan 1, 2017
Primary completion
Dec 31, 2019 (estimated)
Completion
Jun 30, 2020 (estimated)
Last update
Dec 10, 2018

Study contacts

Robert Baughman
Contact
bob.baughman@uc.edu
513-584-5225
Robert Baughman
study chair · University of Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Sarcoidosis→

Other studies from this sponsor

University of Cincinnati

Start the discussion